News

GENDERACTIONplus open letter to support gender equality in research and innovation

Published on
| 2 years ago
Programmes
  • Enhancing EU R&I

The GENDERACTIONplus project wrote an open letter to Ekaterina Zaharieva, European Commissioner-Designate for Start-ups, Research and Innovation, to stress the importance to continue working to expand gender equality policies and ensure that these policies incorporate inclusivity and intersectional perspectives, including maintaining Gender Equality Plans as an eligibility criterion for accessing EU research funding under Horizon Europe, a crucial policy for advancing gender equality in research and higher education institutions.

The open letter can be signed (scroll down below letter) as an individual, with the option to remain anonymous or without affiliation. It is also possible to leave a short comment that could be used for an upcoming social media campaign. Up-to-date the letter has 600 signatories.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2049 articles available Browse all news
  • EIC

EIC Work Programme 2027 adopted

The 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...

Read more
  • Defence
  • DIRS

Start2Def 2026 call open

The Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.